香菊胶囊治疗慢性鼻-鼻窦炎的药物经济学评价  

Pharmacoeconomic evaluation of Xiangju Capsules in treatment of chronic rhinosinusitis

作　　者：刘峘[1] 崔鑫 谢雁鸣[1] 黎元元[1] LIU Huan;CUI Xin;XIE Yan-ming;LI Yuan-yuan(Institute of Basic Rssearch in Clinical Medicine,China Academy of Chinese Medical Sciences,Bejing 100700,China)

机构地区：[1]中国中医科学院中医临床基础医学研究所,北京100700

出　　处：《中国中药杂志》2022年第14期3950-3955,共6页China Journal of Chinese Materia Medica

基　　金：中国中医科学院科技创新工程重大攻关项目(CI2021A00702);国家重点研发计划项目(2018YFC1707400)。

摘　　要：慢性鼻-鼻窦炎(chronic rhinosinusitis, CRS)又称慢性鼻窦炎,是指鼻腔黏膜、鼻窦的慢性非特异性炎症,临床表现出黏脓性鼻涕、鼻塞、嗅觉减退或丧失、头面部胀痛等症,该病病程长、易反复,严重影响患者的身心健康及生活质量。中药复方制剂香菊胶囊功能辛散祛风、清热通窍,临床治疗急慢性鼻窦炎、鼻炎具有良好的有效性和安全性。该文从卫生体系角度出发,基于香菊胶囊治疗鼻窦炎的有效性Meta分析构建了经济性评价模型,对香菊胶囊与常规治疗联合应用治疗慢性鼻窦炎的经济性进行探讨。模型模拟结果显示,采用香菊胶囊联合常规治疗方案治疗平均疗程53 d后,成本较高,产出也较高,计算增量成本效果比(incremental cost-effectiveness ratio, ICER)为263.71元,占我国人均可支配收入的0.82%。采用二阶蒙特卡洛模拟进行概率敏感性分析,验证研究结果较为稳健。研究认为,若以2020年我国人均可支配收入作为患者意愿支付阈值,在一定支付意愿下,慢性鼻-鼻窦炎患者采用香菊胶囊与常规治疗联合方案比单用常规治疗方案更具有经济性。Chronic rhinosinusitis refers to the non-specific inflammation that occurs in the nasal mucosa and sinuses, with clinical manifestations of mucopurulent nasal discharge, nasal congestion, hyposmia or anosmia, and head and face swelling pain.This disease has a long course and is prone to recurrence, which seriously affects the physical and mental health and quality of life of patients.Xiangju Capsules, prepared from infructescence of Platycarya strobilacea(without seeds), Prunellae Spica, Magnoliae Flos, Chuan-xiong Rhizoma, Angelicae Dahuricae Radix, Chrysanthemi Indici Flos, Astragali Radix, etc., are effective in dispelling wind by pungency and dispersing, clearing heat, and relieving orifices, and has good efficacy and safety in the clinical treatment of acute and chronic rhinosinusitis and rhinitis.From the perspective of the health system, an economic evaluation model was constructed based on the Meta-analysis of the effectiveness of Xiangju Capsules in the treatment of chronic rhinosinusitis to discuss the economic efficiency of Xiangju Capsules in combination with conventional treatment or conventional treatment alone in patients with chronic rhinosinusitis.The model simulation results showed that 53 days(average course of treatment) after treatment, Xiangju Capsules combined with conventional treatment had higher cost and higher output, with an incremental cost-effectiveness ratio of CNY 263.71, about 0.82% of per capita disposable income.As revealed by sensitivity analysis results, the research results were robust.As indicated by the findings of this study, Xiangju Capsules combined with conventional treatment for chronic rhinosinusitis patients were more economical than conventional treatment alone based on the assumption that the per capita disposable income of Chinese people in 2020 was the threshold of patients′ willingness to pay.

关 键 词：香菊胶囊 慢性鼻-鼻窦炎 药物经济学 成本-效果分析 上市后评价 

分 类 号：R288[医药卫生—中药学]